Patent Application
20230310408
This application claims the benefit of Indian Provisional Application Serial No. 202011024586, filed Jun. 11, 2021, which is incorporated herein in its entirety.
The present invention generally relates a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from prednisolone and hydroxychloroquine, or a pharmaceutically acceptable salt thereof
Toll-like receptors (TLRs) are a family of pattern recognition receptors that recognize highly conserved components of diverse pathogens and induce innate and adaptive immune responses (Akira S, Takeda K, T. Kaisho, T., Nat Immunol. 2001; 2:675-680; Pandey S, Agrawal D K., Immunol Cell Biol. 2006; 84:333-341; Kawai T, Akira S. J Biochem. 2007; 141:137-145). TLR7 and TLR8 have been shown to be expressed in endosomal compartments and to recognize ssRNA molecular patterns. TLR7 is expressed in B cells and plasmacytoid dendritic cells (pDC); TLR8 is expressed in monocytes and myeloid dendritic cells (mDC) (Chuang T H, Ulevitch R J. Eur Cytokine Net. 2000; 11:372-378; Iwasaki A, Medzhitov R. Nat Immunol. 2004; 5:987-995).
Cutaneous lupus erythematosus (CLE) is a skin disorder which can occur as isolated skin manifestation or with concomitant systemic lupus erythematosus (SLE) (Okon L G, Werth V P. Best Pract Res Clin Rheumatol. 2013; 27:391-404; Cohen M R, Crosby D. J Rheumatol. 1994; 21:1665-1669).
CLE is often associated with the presence of autoantibodies with varying frequency. Similar to SLE, Type I Interferon (IFN) dysregulation is proposed to be a key pathogenic driver in CLE. CLE patients often present with IFN signature in blood and in skin lesions, with blood IFN signature correlating with skin disease activity score (Braunstein I, Klein R, Okawa J, et al., Br J Dermatol. 2012; 166:971-975; Meller S, Winterberg F, Gilliet M, et al., Arthritis Rheum. 2005; 52:1504-1516, Wenzel J, Zahn S, Mikus S, et al., Br J Dermatol. 2007; 157:752-757).
Treatment with sifalimumab (anti-IFNα mAb) and anifrolumab (anti-IFNAR mAb) showed an improvement of skin disease activity scores in SLE patients presenting with cutaneous disease in Phase II clinical trials further supporting the contribution of Type I IFN to the pathogenesis of CLE (Furie R, Khamashta M, Merrill J T, et al. Arthritis Rheumatol. 2017; 69:376-86; Petri M, Wallace D J, Spindler A, et al. Arthritis Rheum. 2013; 65:1011-1021). Plasmacytoid dendritic cells (pDCs) are specialized cells that accumulate in the skin of CLE patients and account for 5-10% of the immune infiltrate and have been proposed to be the major source of Type I IFN in CLE skin lesions. The pDCs robustly secrete IFNα in response to TLR7 and TLR9 stimulation by nucleic acid ligands, while TLR8 induces a variety of myeloid cells to produce proinflammatory cytokines such as TNFα and IL-6 (Siegal F P, Kadowaki N, Shodell M, et al. Science 1999; 284:1835-1837; Tomasini D, Mentzel T, Hantschke M, et al., J Cutan Pathol. 2010; 37:1132-1139; Vermi W, Lonardi S, Morassi M, et al., Immunobiology 2009; 214:877-86).
Apoptotic debris induced by ultra-violet radiation, a well-known environmental trigger of CLE, leads to the accumulation of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) fragments that would activate TLR7 and TLR9 respectively, leading to pDC activation and Type I IFN production (Wenzel J, Proelss J, Wiechert A, et al., J Am Acad Dermatol. 2007; 56: 648-650).
New methods of treating CLE are desired.
Disclosed herein are methods of treating cutaneous lupus erythematosus, comprising administering to a patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of prednisolone or a pharmaceutically acceptable salt thereof.
Also disclosed herein are methods of treating cutaneous lupus erythematosus, comprising administering to a patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of hydroxychloroquine or a pharmaceutically acceptable salt thereof.
The present invention provides methods of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from prednisolone and hydroxychloroquine, or a pharmaceutically acceptable salt thereof.
The present invention provides methods of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of prednisolone or a pharmaceutically acceptable salt thereof.
The present invention provides methods of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of hydroxychloroquine or a pharmaceutically acceptable salt thereof.
These and other features of the invention will be set forth in expanded form as the disclosure continues.
The invention is illustrated by reference to the accompanying drawings described below.
In order that the present description may be more readily understood, certain terms are first defined. Additional definitions are set forth throughout the detailed description.
A “TR7 inhibitor” inhibits the function of TLR7. TLR7 inhibitors can associate with TLR7 reversibly or irreversibly, and include antibodies, small molecules, and millimolecular compounds.
The compound of Formula (I) is a TLR7 inhibitor and has the structure:
The chemical name for the compound of Formula (I) is 2-(4-(2-(7,8-dimethyl-[1,2,4]triazolo[1,5-a]pyridin-6-yl)-3-isopropyl-1H-indol-5-yl)piperidin-1-yl)acetamide. The discovery and synthesis of the compound of Formula (I) is described in WO 2018/005586 A1.
Prednisolone is a corticosteroid drug having the chemical name: 11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydrocyclopenta[a] phenanthren-3-one. Prednisolone can be orally administered as a tablet, an orally disintegrating tablet, a solution, or a suspension. Ophthalmic prednisolone is available as a solution (liquid) and a suspension (eye drops). Prednisolone is available as a sodium salt. Prednisolone can also be administered as the prodrug prednisone. As used herein “prednisolone” includes both prednisolone and prednisone. As used herein “Pred” refers to prednisolone.
Hydroxychloroquine has the structure
As used herein “HCQ” refers to hydroxychloroquine. Hydroxychloroquine is used to treat or prevent auto-immune diseases including lupus and rheumatoid arthritis. It can reduce skin problems in lupus, including cutaneous lupus erythematosus and prevent swelling/pain in arthritis. Hydroxychloroquine is available as a sulfate salt in which 200 mg of the sulfate salt is equal to 155 mg of the base.
Unless otherwise defined, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.
The terms “treat,” “treating,” and “treatment,” as used herein, refer to any type of intervention or process performed on, or administering an active agent to, the patient with the objective of reversing, alleviating, ameliorating, inhibiting, or slowing down or preventing the progression, development, severity or recurrence of a symptom, complication, condition or biochemical indicia associated with a disease. Treatment includes therapeutic treatment and prophylactic or preventative measures, wherein the object is prevent or lessen the targeted condition or disorder.
The term “therapeutically effective amount” or “therapeutically effective dosage” of a drug or therapeutic agent refers to an amount of a drug effective to treat a disease or disorder in a patient. In certain embodiments, an effective amount refers to an amount effective, at dosages and for period of time necessary, achieve the desired therapeutic or prophylactic result. The ability of a therapeutic agent to promote disease regression or inhibit the development or recurrence of the disease can be evaluated using a variety of methods known to the skilled practitioner, such as in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or by assaying the activity of the agent in in vitro assays.
Therapeutically effective amounts of a TLR7 inhibitor, prednisolone, and hydroxychloroquine may vary according to factors such as the disease state, age, sex, and weight of the patient, and abilities of the TLR7 inhibitor, prednisolone, and hydroxychloroquine to elicit a desired response in the patient. Therapeutically effective amounts of the TLR7 inhibitor, prednisolone, and hydroxychloroquine encompasses an amount in which any toxic or detrimental effects of the TLR7 inhibitor, prednisolone, and hydroxychloroquine are outweighed by the therapeutically beneficial effects.
The terms “administering” and “administration” refers to the physical introduction of a composition comprising a therapeutic agent to a patient, using any of the various methods and delivery systems known to those skilled in the art. Routes of administration for the TLR7 inhibitor and the second agent include enteral, topical, and mucosal administration such as oral, topical, sublingual, rectal, intranasal, and intravenous administration, and parenteral administration such as intravenous, intramuscular, and subcutaneous injection.
Administration “in combination with” one or more further therapeutic agents includes simultaneous (concurrent) and consecutive (sequential) administration in any order. For example, the patient may swallow the oral dosage form of the TLR7 inhibitor and the oral dosage form for the second agent in either order (consecutive); or may swallow both oral dosage forms together (concurrent).
The term “patient” includes human and other mammalian subjects that receive therapeutic treatment.
The features and advantages of the invention may be more readily understood by those of ordinary skill in the art upon reading the following detailed description. It is to be appreciated that certain features of the invention that are, for clarity reasons, described above and below in the context of separate embodiments, may also be combined to form a single embodiment. Conversely, various features of the invention that are, for brevity reasons, described in the context of a single embodiment, may also be combined so as to form sub-combinations thereof. Embodiments identified herein as exemplary or preferred are intended to be illustrative and not limiting.
Provided herein are one or more methods of treating a patient having cutaneous lupus erythematosus.
One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof; and a therapeutically effective dose of a second agent selected from prednisolone and hydroxychloroquine, or a pharmaceutically acceptable salt thereof.
One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of prednisolone or a pharmaceutically acceptable salt thereof. Included in this embodiment is a method in which the TLR7 inhibitor is the compound of Formula (I).
One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of prednisone or a pharmaceutically acceptable salt thereof. Included in this embodiment is a method in which the TLR7 inhibitor is the compound of Formula (I).
One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of hydroxychloroquine or a pharmaceutically acceptable salt thereof. Included in this embodiment is a method in which the TLR7 inhibitor is the compound of Formula (I).
One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from prednisolone and hydroxychloroquine, or a pharmaceutically acceptable salt thereof, wherein said second agent is administered simultaneously with said TLR7 inhibitor. Included in this embodiment is a method in which the TLR7 inhibitor is the compound of Formula (I).
One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from prednisolone or a pharmaceutically acceptable salt thereof, wherein said second agent is administered simultaneously with said TLR7 inhibitor. Included in this embodiment is a method in which the TLR7 inhibitor is the compound of Formula (I).
One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from hydroxychloroquine, or a pharmaceutically acceptable salt thereof, wherein said second agent is administered simultaneously with said TLR7 inhibitor. Included in this embodiment is a method in which the TLR7 inhibitor is the compound of Formula (I).
One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from prednisolone and hydroxychloroquine, or a pharmaceutically acceptable salt thereof, wherein said second agent is administered sequentially with said TLR7 inhibitor. Included in this embodiment is a method in which the TLR7 inhibitor is administered prior to the administration of the second agent. Also included in this embodiment is a method in which the TLR7 agent is administered after the second agent. Additionally, included in this embodiment is a method in which TLR7 inhibitor is the compound of Formula (I).
One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from prednisolone or a pharmaceutically acceptable salt thereof, wherein said second agent is administered sequentially with said TLR7 inhibitor. Included in this embodiment is a method in which the TLR7 inhibitor is administered prior to the administration of the second agent. Also included in this embodiment is a method in which the TLR7 agent is administered after the second agent. Additionally, included in this embodiment is a method in which TLR7 inhibitor is the compound of Formula (I).
One embodiment provides a method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from hydroxychloroquine or a pharmaceutically acceptable salt thereof, wherein said second agent is administered sequentially with said TLR7 inhibitor. Included in this embodiment is a method in which the TLR7 inhibitor is administered prior to the administration of the second agent. Also included in this embodiment is a method in which the TLR7 agent is administered after the second agent. Additionally, included in this embodiment is a method in which TLR7 inhibitor is the compound of Formula (I).
In one embodiment, a therapeutically effective dose of the compound of Formula (I) is in the range of 0.1 to 100 mg.
In one embodiment, a therapeutically effective dose of the compound of prednisolone is in the range of 0.5 to 50 mg.
In one embodiment, a therapeutically effective dose of the compound of hydroxychloroquine is in the range of 1 to 20 mg.
The therapeutically effective dose of the TL7 inhibitor can be administered as a single daily dose (q.d.), divided and administered twice daily (b.i.d.), or divided and administered as three or more doses per day.
The therapeutically effective dose of prednisolone can be administered as a single daily dose (q.d.), divided and administered twice daily (b.i.d.), or divided and administered as three or more doses per day.
The therapeutically effective dose of hydroxychloroquine can be administered as a single daily dose (q.d.), divided and administered twice daily (b.i.d.), or divided and administered as three or more doses per day.
In one embodiment, the therapeutically effective dose of the TLR7 inhibitor is administered as a single daily dose.
In one embodiment, the therapeutically effective dose of the compound of Formula (I) is administered as a single daily dose.
In one embodiment, the therapeutically effective dose of prednisolone is administered as a single daily dose.
In one embodiment, the therapeutically effective dose of hydroxychloroquine is administered as a single daily dose.
In one embodiment, the therapeutically effective dose of the TLR7 inhibitor is administered as a single daily dose and the therapeutically effective dose of the second agent selected from prednisolone and hydroxychloroquine is administered as a single dose. Included in this embodiment, is a method in which the TLR7 inhibitor and the second agent are administered once a day, wherein the TLR7 inhibitor and the second agent are administered simultaneously, or the TLR7 inhibitor is administered immediately before or after the administration of the second agent. Also include in this embodiment is a method in which the TLR7 inhibitor is the compound of Formula (I). Additionally, included in this embodiment is a method in which the second agent is prednisolone. Further, included in this embodiment is a method in which the second agent is hydroxychloroquine.
In one embodiment, a therapeutically effective dose of prednisolone is administered as a single daily dose.
In one embodiment, a therapeutically effective dose of hydroxychloroquine is administered as a single daily dose.
In one embodiment, the therapeutically effective dose of the TLR7 inhibitor is administered as a twice daily dose and the therapeutically effective dose of the second agent is administered either one or twice daily dose. Included in this embodiment is a method in which the TLR7 inhibitor is the compound of Formula (I).
In one embodiment, the therapeutically effective dose of the TLR7 inhibitor is administered as a twice daily dose and the therapeutically effective dose of the second agent selected from prednisolone and hydroxychloroquine is administered as a twice dose. Included in this embodiment, is a method in which the TLR7 inhibitor and the second agent are administered twice a day, wherein the TLR7 inhibitor and the second agent are administered simultaneously twice daily, or the TLR7 inhibitor is administered immediately before or after the administration of the second agent twice daily. Also include in this embodiment is a method in which the TLR7 inhibitor is the compound of Formula (I). Additionally, included in this embodiment is a method in which the second agent is prednisolone. Further, included in this embodiment is a method in which the second agent is hydroxychloroquine.
In an another embodiment, the method of treating a patient having cutaneous lupus erythematosus, comprising administering to said patient a therapeutically effective dose of a TLR7 inhibitor or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective dose of a second agent selected from prednisolone and hydroxychloroquine, or a pharmaceutically acceptable salt thereof, and in combination with one or more addition third agents. Examples of suitable third agents include corticosteroids, rolipram, calphostin, cytokine-suppressive anti-inflammatory drugs (CSAIDs), Interleukin-10, glucocorticoids, salicylates, nitric oxide, and other immunosuppressants; nuclear translocation inhibitors, such as deoxyspergualin (DSG); nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, celecoxib and rofecoxib; steroids such as dexamethasone; antiproliferative agents such as methotrexate, leflunomide, FK506 (tacrolimus, PROGRAF®); cytotoxic drugs such as azathiprine and cyclophosphamide; TNF-α inhibitors such as tenidap, anti-TNF antibodies or soluble TNF receptor, and rapamycin (sirolimus or RAPAMUNE®) or derivatives thereof. The above third agents, when employed in combination with the combinations of Compound (I) and the second agent, may be used, for example, in those amounts indicated in the Physicians' Desk Reference (PDR) or as otherwise determined by one of ordinary skill in the art. In the methods of the present invention, the one or more third agents may be administered prior to, simultaneously with, or following the administration of Compound (I) or the second agent.
All the animal experimental procedures were reviewed and approved by the Institutional Animal Ethics Committee (IAEC) and conducted in accordance with procedures set by the Committee For The Purpose of Control and Supervision on Experiments on Animals (CPCSEA). Mice were group housed in Syngene Laboratory Animal Research Facility (SLAR, Bangalore India; AAALAC accredited), and maintained under normal 12 h light/12 h dark cycle with ad libitum access to food and water. At the end of the studies, animals were euthanized by CO2 asphyxiation for plasma and tissue collection.
Female MRL/lpr mice of 12 to 14 weeks of age were screened and randomized based on the titers of anti-dsDNA antibodies and urinary neutrophil gelatinase-associated lipocalin (NGAL). Mice were treated orally, once daily for 8 weeks with vehicle (10% ethanol; 45% PEG 300; 5% Pluronic F-68; 40% 20 mM citrate buffer) or different doses of test compound (Compound (I)) or reference (prednisolone) compound. The effect of vehicle, test or reference compounds on cutaneous disease severity were assessed by evaluating skin lesions on the neck, head, face and ear separately. The severity of skin lesions was assessed every week by counting the number of lesions as well as erythema (on the scale of 0 to 4, considering zero—none; 1—mild, 2—moderate, 3—moderate to severe and 4—very marked and severe). Total erythema was derived by adding the erythema scores of neck, head, ear and face lesions. Since female MRL/lpr mice also develop nephritis in addition to cutaneous lesions, the effect of vehicle, test or reference compounds on renal disease were evaluated by measuring proteinuria, urinary NGAL and autoantibody titers like anti-Ro, anti-smRNP and anti-dsDNA Ab titer. One week before termination of the experiment, mice were bled at various time points to capture the complete pharmacokinetic profile of the test or reference compound and also the extent of inhibition of gardiquimod-induced IL-6 in an ex vivo whole blood assay. Spleen samples were taken at the end of the study to measure the impact of treatment on IL-6 and IFNα-producing cell population by flow cytometry. Blood samples were analyzed for gene expression by qPCR and for TLR7 target coverage utilizing an ex vivo blood assay of gardiquimod induced IL-6 production. Statistical analysis was done using one-way ANOVA with Dunnett's test to calculate the significance of test or reference compound treated groups vs. vehicle control group. Percent reduction in disease severity was calculated for each parameter, for test or reference compound treated groups vs. vehicle control group.
Female MRL/lpr mice develop cutaneous lesions in a spontaneous manner, making this a widely accepted preclinical murine model of cutaneous lupus. In addition to cutaneous manifestations, these mice also showed kidney injury. Compound was investigated for its effects on both skin lesions and on kidney injury markers in this model. In this study, mice were randomized based on urinary NGAL and anti-dsDNA Ab titer. Immediately after recruitment, mice were treated with Compound (I) and prednisolone for 8 weeks.
Treatment with Compound (I) improved survival of mice in Female MRL/lpr model of lupus compared to vehicle
The data in Table 1 shows that treatment with Compound (I) improved survival of the mice in this study. Whereas only 87% of vehicle mice survived for 8 weeks, mice receiving doses of 0.25 and 0.75 mg/kg of Compound (I) achieved 100% survival.
As shown in
Dose-dependent inhibition of cutaneous lesions including number of lesions as well as erythema of lesions was observed with treatment with Compound (I) in mice. Greater efficacy was observed with 0.25 mg/kg and 0.75 mg/kg doses of Compound (I). These two doses resulted in improved survival, 100% versus 87% survival of vehicle treated mice. At these doses, Compound (I) showed suppression of lupus nephritis as assessed by kidney injury markers like proteinuria and urinary NGAL. Additionally, at these two doses, Compound (I) showed significant suppression of anti-dsDNA, anti-RO and anti-smRNP auto-antibody titers and inhibited Type I IFN response gene expression.
Female MRL/lpr mice of 15 weeks of age were treated for 5 weeks. Mice were recruited when they showed group average of total skin lesions score as 1.5 to 2. Total skin lesions score includes cumulative score of Neck/Back, Face, Head and Ear lesions
2. Combination Studies of Compound (I) with Prednisolone and Compound (I) with Hydroxychloroquine (HQC) in MRL/Lpr Model of Lupus—Advanced Disease
Female MRL/lpr mice of 16 weeks of age were treated for 5 weeks. Mice were recruited when they showed group average of total skin lesions score as 2 to 2.5. Total skin lesions score includes cumulative score of Neck/Back, Face, Head and Ear lesions. Table 2 shows the treatments, doses, and number of mice in each treatment group.
| Number | Date | Country | Kind |
|---|---|---|---|
| 202011024586 | Jun 2020 | IN | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US2021/036740 | 6/10/2021 | WO |
